PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT ID: NCT02804776

Last Updated: 2021-06-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-27
• Study Completion Date: 2018-02-21

Brief Summary

This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.

Detailed Description

Selected patients will receive 4 weeks of gefitinib before surgery. A Positron Emission Tomography - Computed Tomography (PET- CT) will be performed before and after gefitinib to assess the response. Circulating tumour cells (CTCs) and plasma Deoxyribonucleic acid (DNA) will be acquired at baseline, 2 weeks and 4 weeks after gefitinib treatment. Resected tumor will be sectored in details to study the spatial heterogeneity.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gefitinib

Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery

Group Type: EXPERIMENTAL

Gefitinib

Intervention Type: DRUG

250mg oral daily for 4 weeks

Interventions

Gefitinib

250mg oral daily for 4 weeks

Intervention Type: DRUG

Other Intervention Names

Iressa

Eligibility Criteria

Inclusion Criteria

• EGFR mutation positive Non-Small Cell lung cancer (NSCLC) (regardless of smoking status), or control group may encompass other molecular subtypes of lung cancer e.g. anaplastic lymphoma kinase (ALK) and Kirsten rat sarcoma viral oncogene homolog (KRAS).
• All early stage patients with NSCLC who are deemed surgically resectable.
• All patients must have histologically proven NSCLC, with known EGFR mutation
• Patients should be fit for either lobectomy/ pneumonectomy with or without lymph node sampling.
• Primary tumour should be at least 2 cm in size (Tumor stage 1b).
• Willing to provide informed consent.

Exclusion Criteria

• Known severe hypersensitivity to gefitinib or any of the excipients of this product
• Any serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
• Interstitial lung disease (ILD) or pulmonary fibrosis; impaired pulmonary function (e.g. FEV1 <40% predicted value, artery blood gas PaO2<60mmHg)
• Patients with prior exposure to agents directed at the Human epidermal receptor (HER) axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
• Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer therapy (e.g. monoclonal antibody therapy) for lung cancer.
• Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within six months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
• Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications.
• Patient who has serious active infection.
• Patients who harbouring exon 20 T(Threonine)790M (Methionine) mutation.
• Pregnancy or breast feeding.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Centre, Singapore

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel SW Tan

Role: PRINCIPAL_INVESTIGATOR

National Cancer Centre, Singapore

Locations

National Cancer Centre

Singapore, , Singapore

Countries

Singapore

Other Identifiers

ECRU-LUNG-2013

Identifier Type: -

Identifier Source: org_study_id